M. Navarro

UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy

Eva Martinez‐Balibrea, Albert Abad, Anna Martínez‐Cardús et al. · British Journal of Cancer · 2010 · 88 citations · Full text

Tyms Genetic Variants, Oncology, Oncogenic Agent +8

Clinicopathological risk factors of Stage II colon cancer: results of a prospective study

Cristina Santos, Adriana López‐Doriga, M. Navarro et al. · Colorectal Disease · 2012 · 40 citations

Mutations in TP53 are a prognostic factor in colorectal hepatic metastases undergoing surgical resection

Teresa Serrano, M. Morell, Joan Valls et al. · Carcinogenesis · 2007 · 40 citations

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, M. Martínez-Villacampa et al. · Annals of Oncology · 2008 · 27 citations

Oncology, Digestive Tumors Study, Gastrointestinal Oncology +10

The oncology acute toxicity unit (OATU): an outpatient facility for improving the management of chemotherapy toxicity

Margarita Majem, Maica Galán, S Chicote et al. · Clinical & Translational Oncology · 2007 · 24 citations

Medicine, Chemotherapy Toxicity, Cancer Management +9